Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties will be auctioned on May 28, 2010.  The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors.  He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.  

EP-2104R is a gadolinium-based MRI thrombus imaging agent with a potential indication for stroke workup.  It is a first-in-class fibrin binding agent that has completed a Phase 2 proof-of-concept study.          

SOURCE Joseph F. Finn, Jr., C.P.A.